Surface Coating Approach to Overcome Mucosal Entrapment of DNA Nanoparticles for Oral Gene Delivery of Glucagon-like Peptide 1

2019 ◽  
Vol 11 (33) ◽  
pp. 29593-29603 ◽  
Author(s):  
Tianqi Nie ◽  
Zhiyu He ◽  
Yang Zhou ◽  
Jinchang Zhu ◽  
Kuntao Chen ◽  
...  
Keyword(s):  
Gene Delivery ◽  
Surface Coating ◽  
Dna Nanoparticles ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals A Genetically Modified Skin Graft for Treating Alcohol Use Disorder and/or Polysubstance Abuse With Cocaine

2021 ◽  
Vol 11 ◽  
Author(s):  
Qingyao Kong ◽  
Xiaoyang Wu ◽  
Ming Xu
Keyword(s):  
Alcohol Use ◽  
Gene Delivery ◽  
Alcohol Use Disorder ◽  
Genetically Modified ◽  
Unmet Need ◽  
Delivery Platform ◽  
Polysubstance Abuse ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Grafting Procedure

Alcohol use disorder (AUD) is one of the foremost public health problems. Alcohol is also frequently co-abused with cocaine. There is a huge unmet need for the treatment of AUD and/or cocaine co-abuse. We have developed and used a skin stem cell-based gene delivery platform and found that production of the glucagon-like peptide-1 (GLP1) from the grafted genetically modified skin reduced development and reinstatement of alcohol-induced drug-taking and seeking, voluntary oral alcohol consumption and alcohol-induced increase in dopamine (DA) levels in the nucleus accumbens (NAc). Moreover, we have developed a novel co-grafting procedure for both modified human butyrylcholinesterase (hBChE)- and GLP1-expressing cells. Skin grafts-derived hBChE and GLP1 reduced acquisition of drug-taking and toxicity induced by concurrent alcohol and cocaine injections. These results imply that gene delivery through skin transplants may add a new option to treat drug abuse and co-abuse.

Effects of glucagon-like peptide-1 (GLP-1) on gastric accommodation, emptying and satiety in humans

2001 ◽  
Vol 120 (5) ◽  
pp. A74-A74
Author(s):  
S AROS ◽  
D KIM ◽  
D BURTON ◽  
G THOMFORDE ◽  
A VELLA ◽  
...  
Keyword(s):  
Gastric Accommodation ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Eine häufige genetische Variation in WFS1 bedingt eine gestörte Glucagon-like Peptide-1-induzierte Insulinsekretion

2009 ◽  
Vol 4 (S 01) ◽  
Author(s):  
K Müssig ◽  
SA Schäfer ◽  
H Staiger ◽  
F Machicao ◽  
N Stefan ◽  
...  
Keyword(s):  
Genetische Variation ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Dulaglutide, a glucagon-like peptide-1 receptor agonist: in the search for survival molecule

2020 ◽  
Vol 9 (2) ◽  
pp. 49-58
Author(s):  
A.S. Ametov ◽  
◽  
A.O. Nevolnikova ◽  
E.A. Tertychnaya ◽  
O.A. Mishra ◽  
...  
Keyword(s):  
Receptor Agonist ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Liraglutide, a glucagon-like peptide-1 receptor agonist, improves bone mass and architecture in ovariectomised mice

2014 ◽  
Author(s):  
Marie Pereira ◽  
Jeshmi Jeyabalan ◽  
Camilla Sofie Jorgensen ◽  
Mark Cleasby ◽  
Mark Hopkinson ◽  
...  
Keyword(s):  
Bone Mass ◽  
Receptor Agonist ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Effect of bariatric surgery on serum glucagon like peptide-1 concentration and metabolic parameters among obese type 2 diabetics

2013 ◽  
Author(s):  
Salah El Din Shelbaya ◽  
Alaa Abbas Mostafa ◽  
Salwa Seddik ◽  
Manal M. Abu Shady ◽  
Meram M. Bekhet ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Metabolic Parameters ◽  
Type 2 Diabetics ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1
Sign in / Sign up

Export Citation Format

Share Document